Arthneeti
Syngene International LtdQ3 FY24

Syngene International Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹361P/E: 51.6Market Cap: ₹15.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Syngene International Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Syngene International Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Syngene International Ltd — get its next earnings analysis in your feed

How does Syngene International Ltd rank vs peers in Healthcare Services?

Pro feature
ThisSyngene International Ltd
See where Syngene International Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Syngene International Ltd rank in Healthcare Services?

Compare Syngene International Ltd against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Continue your research

What Syngene International Ltd's management said in earlier quarters

Others in Healthcare Services this season

  • KMC Speciality Hospitals (India) Ltd (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • KMC Speciality Hospitals (India) Ltd (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • Suven Life Sciences Ltd (Q1 FY22)

    The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…

  • Vimta Labs Ltd (Q3 FY25)

    Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →